Invivyd Announces New Public Offering of Common Stock
Invivyd, Inc. (NASDAQ: IVVD), a leading biopharmaceutical company, has begun an underwritten public offering of its common stock. This strategic move could help the company bolster its financial standing and support ongoing research efforts.
Details About the Offering
The offering includes an option for underwriters to purchase an additional 15% of shares sold at the public offering price, minus underwriting discounts and commissions. Invivyd, which is solely offering the shares, has indicated that the offering is subject to market conditions, without any guarantees regarding its completion or terms.
Utilization of Proceeds
The funds raised from this offering are intended for several critical initiatives. Invivyd plans to allocate the proceeds towards trial protocol development, advancements in the VYD2311 clinical program, and ongoing research into viral treatment pipelines, particularly those focusing on respiratory syncytial virus (RSV) and measles. Further, the funds will support efforts in the Spike Protein Elimination and Recovery (SPEAR) Study Group, which investigates the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, along with general corporate needs.
The Role of Cantor Fitzgerald
In this operation, Cantor Fitzgerald has taken on the role of the sole book-running manager. Their expertise will be crucial in guiding the process and ensuring that the offering achieves its intended goals.
Regulatory Aspects
The shares are offered under a shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) and has been effective since late 2022. The offering will only be finalized through a prospectus supplement, which will be filed with the SEC along with details that further describe the terms of the sale.
About Invivyd's Innovations
Invivyd is dedicated to creating groundbreaking solutions against serious viral infections, particularly SARS-CoV-2. With a proprietary integrated technology platform, the company is positioned uniquely within the biopharmaceutical industry to develop top-tier antibodies. In early 2024, Invivyd obtained emergency use authorization for a monoclonal antibody, marking a significant milestone in their endeavor to combat viral diseases.
Frequently Asked Questions
What is the purpose of Invivyd's new stock offering?
The stock offering is intended to raise funds for trial development, advancement of clinical programs, and research into viral treatment options.
Who is managing the stock offering?
Cantor Fitzgerald is acting as the sole book-running manager for Invivyd's public offering of common stock.
How will the funds from the offering be utilized?
The proceeds will support clinical trials, research on viral infections, and general corporate purposes.
What regulatory body oversees this offering?
The U.S. Securities and Exchange Commission (SEC) is the governing body for the offering of these shares.
What technology does Invivyd utilize?
Invivyd employs a proprietary integrated technology platform designed for the development of high-quality therapeutic antibodies.
